drugset / Trial / NCT01693679
Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
• To estimate renoprotective efficacy of Telbivudine treated patients with HBV-related liver cirrhosis.
Timeline
- Start
- 2012-09
- Primary completion
- 2014-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adefovir | Unknown | 10 mg | Oral |
| Subject | Enecavir | Unknown | 0.5 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 100 mg | Oral |
| Subject | Telbivudine | Small molecule | 600 mg | Oral |